KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue: 2009-2023

Historic Current Deferred Revenue for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2023 value amounting to $4,000.

  • Jazz Pharmaceuticals' Current Deferred Revenue fell 99.59% to $4,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $4,000, marking a year-over-year decrease of 99.59%. This contributed to the annual value of $463,000 for FY2022, which is 81.89% down from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $4,000 for Q3 2023, which was down 0.00% from $4,000 recorded in Q2 2023.
  • Jazz Pharmaceuticals' 5-year Current Deferred Revenue high stood at $13.1 million for Q1 2019, and its period low was $4,000 during Q1 2023.
  • Moreover, its 3-year median value for Current Deferred Revenue was $1.5 million (2022), whereas its average is $1.7 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first spiked by 88.06% in 2019, then plummeted by 99.80% in 2023.
  • Jazz Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $9.6 million in 2019, then slumped by 49.26% to $4.9 million in 2020, then plummeted by 47.42% to $2.6 million in 2021, then slumped by 81.89% to $463,000 in 2022, then slumped by 99.59% to $4,000 in 2023.
  • Its last three reported values are $4,000 in Q3 2023, $4,000 for Q2 2023, and $4,000 during Q1 2023.